The Global Vaccine Contract Manufacturing Market size is estimated to be worth USD 1476.3 million by 2026 from USD 990.9 million in 2021. It is expected to rise at a CAGR of 8.3% during the forecast period.
A vaccine is a biological element prepared to assist the immunity of a person against one or several diseases. Contracted Vaccine manufacturing establishment has higher qualitative and quantitative controlling standards with a significant margin of fixed costs, and production & development linked difficulties, have limited competition between vaccine manufacturers.
MARKET DRIVERS:
Y-o-Y growth in the number of R&D activities for novel vaccines, rising biotechnology advancements, and the latest technological developments are majorly escalating the global vaccine contract manufacturing market.
According to the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), in 2020, research-based pharmaceutical industries have been engaged 2 million and above for research and development and offer medicines that advance their lives globally. The demand for contract manufacturing is increasing significantly, which in turn drives market growth globally. Factors such as growing demand for vaccines worldwide and Y-O-Y growth in chronic disease incidence are further propelling the global vaccine contract manufacturing market.
The growing number of infectious diseases such as COVID19 and hepatitis-B is accelerating the global vaccine contract manufacturing market growth rate. Rising awareness levels regarding the vaccines' advantages among developed countries is expected to impact the vaccine contract manufacturing market growth positively.
MARKET RESTRAINTS:
However, issues associated with the manufacturing setups and vaccine production hinder the vaccine contract manufacturing market growth. The costs associated with the vaccination and patent expiration may negatively impact the market growth during the forecast period. Strict regulatory guidelines united with prominent rigid cost, production, and advancements-related hurdles have an incomplete contest between vaccine manufacturers.
Impact of COVID-19 on the global vaccine contract manufacturing market:
The novel coronavirus (COVID19) has created a positive impact on the vaccine contract manufacturing market. As the GlobalData Pharma Intelligence Centre, the pharmaceutical companies have recognized 42 contract manufacturing service terms and conditions for 26 sequence COVID-19 vaccines. In March 2020, LabCorp introduced the NAA test to identify coronavirus in the United States. The NAA test is coupled in patient care, and the virus is to spread continuously. The industry is concentrating on novel drug discovery, test kits, and assisting the advancements of vaccines and treatments for COVID 19 across the Covance Drug Development business to develop patients' health and lives.
REPORT COVERAGE:
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2020 to 2026 |
|
Base Year |
2020 |
|
Forecast Period |
2021 to 2026 |
|
Segments Covered |
By Service Type, Product Type, Vaccine Type, and Region |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
|
Regions Covered |
North America, Europe, Asia Pacific, Latin America, Middle East, and Africa |
This research report on the global vaccine contract manufacturing market has been segmented and sub-segmented based on the service type, product type, vaccine type, and region.
Vaccine Contract Manufacturing Market - By Service Type:
The full Finish service type segment is expected to account for the largest share in the global vaccine contract manufacturing market during the forecast period based on the service type.
Vaccine Contract Manufacturing Market - By Product Type:
The single vaccine product type is more familiar amid the vaccine contract manufacturing market.
Global Vaccine Contract Manufacturing Market – By Vaccine Type:
Based on the vaccine type, the live attenuated vaccines segment is estimated to grow at a substantial CAGR during the assessment period. Due to many licensed oral or intranasal administration products, the segment's growth is the potentiality to induce appropriate handling circumstances about preservation.
The inactivated vaccines segment was the market leader in 2019. These vaccines are protective and relatively more stable than other types.
The subunit vaccines segment to register a stable growth rate during the forecast period due to continuous research to develop re-combination subunit vaccines opposing the Hepatitis C virus.
Global Vaccine Contract Manufacturing Market – By Region:
Regionally, North America takeovers the global market, having the existence of a large number of contract manufacturing organizations (CMOS). About 40 CMOs are present in diverse locations in the U.S. Europe is the next major market for vaccine contract manufacturing, with about 20 CMOs located in Germany, U.K, and France. The Asia Pacific market is about to expand at a high growth rate throughout the forecast period due to the rapidly growing economies of India and China.
KEY MARKET PARTICIPANTS:
Some of the key competitors operating in the global vaccine contract manufacturing market profiled in this report are Thomas Jefferson University, Goodwin Biotechnology Inc., BioMARK, Emergent BioSolutions, Soligenix Inc., Catalent Biologics, Minneapolis Medical Research Foundation (MMRF), Bavarian Nordic A/S, and FUJIFILM Diosynth Biotechnologies.
RECENT MARKET HAPPENINGS :
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Service Type
5.1.1 Introduction
5.1.2 Bulk Product
5.1.3 Fill Finish
5.1.4 Y-o-Y Growth Analysis, By Service Type
5.1.5 Market Attractiveness Analysis, By Service Type
5.1.6 Market Share Analysis, By Service Type
5.2 Product Type
5.2.1 Introduction
5.2.2 Single Vaccine
5.2.2.1 Influenza Virus
5.2.2.2 Chicken Pox
5.2.2.3 Ebola Virus
5.2.2.4 Tetanus
5.2.2.5 Tuberculosis
5.2.2.6 Polio
5.2.2.7 Small Pox
5.2.3 Combination Vaccine
5.2.4 Y-o-Y Growth Analysis, By Product Type
5.2.5 Market Attractiveness Analysis, By Product Type
5.2.6 Market Share Analysis, By Product Type
5.3 Vaccine Type
5.3.1 Introduction
5.3.2 Inactivated Vaccines
5.3.3 Conjugate Vaccines
5.3.4 Live Attenuated
5.3.5 Toxoid Vaccines
5.3.6 Recombinant Vector Vaccines
5.3.7 Subunit Vaccines
5.3.8 Synthetic Vaccines
5.3.9 Y-o-Y Growth Analysis, By Vaccine Type
5.3.10 Market Attractiveness Analysis, By Vaccine Type
5.3.11 Market Share Analysis, By Vaccine Type
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Service Type
6.1.3.3 By Product Type
6.1.3.4 By Vaccine Type
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Service Type
6.1.4.3 By Product Type
6.1.4.4 By Vaccine Type
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Service Type
6.1.5.3 By Product Type
6.1.5.4 By Vaccine Type
6.2 North America
6.1.1 Introduction
6.1.2 United States
6.1.3 Canada
6.3 Europe
6.2.1 Introduction
6.2.2 U.K
6.2.3 Spain
6.2.4 Germany
6.2.5 Italy
6.2.6 France
6.4 Asia-Pacific
6.3.1 Introduction
6.3.2 China
6.3.3 India
6.3.4 Japan
6.3.5 Australia
6.3.6 South Korea
6.5 Latin America
6.4.1 Introduction
6.4.2 Brazil
6.4.3 Argentina
6.4.4 Mexico
6.4.5 Rest of Latin America
6.6 Middle East & Africa
6.5.1 Introduction
6.5.2 Middle-East
6.5.3 Africa
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Bavarian Nordic A/S
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Thomas Jefferson University
8.3 Goodwin Biotechnology Inc.
8.4 BioMARK
8.5 Emergent BioSolutions
8.6 Soligenix Inc.
8.7 Catalent Biologics
8.8 Minneapolis Medical Research Foundation
8.9 FUJIFILM Diosynth Biotechnologies
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
